uniQure Q3 2021 Earnings Report
Key Takeaways
uniQure reported its financial results for the third quarter of 2021. The company held cash and cash equivalents of $578.5 million as of September 30, 2021. Revenue for the quarter was $2.0 million, and the net loss was $36.5 million, or $0.79 basic and diluted net loss per share.
Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021.
Enrolled 14 patients to date in Phase 1/2 clinical trial of AMT-130 in Huntington’s Disease, with no significant safety concerns observed.
Preliminary data on first four patients in ongoing Phase I/II clinical trial of AMT-130 and initiation of European Phase Ib/II clinical trial expected by year-end 2021.
Closed acquisition of Corlieve Therapeutics adding preclinical program in temporal lobe epilepsy to proprietary research pipeline.
uniQure
uniQure
Forward Guidance
uniQure expects to announce clinical data from its Huntington’s disease gene therapy program, including preliminary data on the first four patients in its ongoing U.S. Phase I/II study of AMT-130. Additionally, top-line 78-week follow-up data on all HOPE-B pivotal study patients is expected to be announced by CSL Behring in late 4Q2021.